No Data
No Data
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. 2024 Interim Report
Summary of the Semi-Annual Report of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. for 2024
Zhejiang Jiuzhou Pharmaceutical (603456.SH): Net income in the first half of the year was 0.475 billion yuan, a decrease of 23.62% year-on-year.
On August 26th, Jiuzhou Pharmaceutical (603456.SH) released its semi-annual report. During the reporting period, the company achieved revenue of 2.764 billion yuan, a decrease of 15.07% compared to the previous year; the net income attributable to the parent company was 0.475 billion yuan, a decrease of 23.62% compared to the previous year. During the reporting period, the company was awarded multiple honors, including being ranked in the top 20 CDMO enterprises in the 2024 China Medicine market, being listed in the top 100 Chinese pharmaceutical industry companies of 2023 - 2023 China CXO Enterprise TOP20, and being recognized as a leading company in the biomedicine industry in Zhejiang Province.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): no drugs for the treatment of prostate
Zhejiang Jiuzhou Pharmaceutical (603456.SH) stated on the investor interaction platform that the company does not have any drugs for treating prostate.
Zhejiang Jiuzhou Pharmaceutical (603456.SH): No products related to monkeypox virus are available.
On August 15th, Gelunhui reported that zhejiang jiuzhou pharmaceutical (603456.SH) stated on the investor interaction platform that the company has no products related to monkeypox virus.
Is Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Using Too Much Debt?
No Data